Evren Technologies Appoints Dr. Laura Rice to Scientific Advisory Board

Gainesville, FL – June 12, 2025– Evren Technologies, a medical technology company developing next-generation solutions for mental health conditions through non-invasive neuromodulation, proudly announces the appointment of Dr. Laura Rice to its Scientific Advisory Board. Dr. Rice brings deep interdisciplinary expertise spanning neuroscience, regulatory science, and translational medical device research, strengthening Evren’s commitment to scientific rigor and patient-centered innovation.

Dr. Rice is the CEO of LR Consulting Group, LLC, where she advises medical device companies and academic researchers on FDA regulatory pathways and clinical study design, particularly for neurostimulation and software as a medical device (SaMD). She previously served as Acting Senior Lead Scientific Reviewer at the FDA’s Center for Devices and Radiological Health, specializing in pre-market evaluations of neuromodulation devices for psychiatric indications, including PTSD.

“We are honored to welcome Dr. Laura Rice to our Scientific Advisory Board,” said Rick Giancola, CEO of Evren Technologies. “Her combined background in clinical neuroscience, neurotechnology, and regulatory strategy aligns seamlessly with our mission to bring evidence-based, accessible therapies to individuals living with PTSD.”

Dr. Rice earned her Ph.D. in Behavior, Cognition, and Neuroscience from American University, where her research explored cerebellar contributions to social prediction and learning in autism. She holds multiple advanced degrees, including a Master of Arts in Psychology, a Data Science Graduate Certificate, and a Bachelor of Science in Chemical Engineering from UMBC. Most recently, she completed a postdoctoral fellowship in Neurology at the Johns Hopkins School of Medicine, focusing on neurodevelopmental disorders and high-resolution neuroimaging.

Her academic work has included leading roles in NIH-funded research, first-author publications on cerebellar imaging, and mentorship of early-career scientists. Dr. Rice also serves as a peer reviewer for leading neuroscience journals, including Cerebral Cortex, Neuroimage: Clinical, and Nature Reviews Neurology.

"I’m excited to join the Evren Technologies Scientific Advisory Board at such a critical stage of growth," said Dr. Rice. "The development of innovative, wearable neuromodulation tools has the potential to enrich the treatment of trauma-related conditions and provide greater accessibility. I look forward to contributing to the science and strategy behind this important work."

About Evren Technologies

Evren is a bioelectronic medical device company in the field of neuromodulation devices and is transforming the treatment of PTSD, Acute Stress Reactions, Acute Stress Disorder, and Adjustment Disorders by delivering noninvasive, breakthrough, Vagal Nerve Stimulation (VNS) to the auricular branch of the vagus nerve.  Our initial product -- the Phoenix® CR – administers transcutaneous auricular VNS (taVNS) safely and effectively in laboratory, clinical, and unsupervised home settings for VNS research use and was launched in late 2023.  The Phoenix CR will also be the clinical trial device in Evren’s pivotal trial seeking De Novo classification from the FDA.  It will deliver safe and effective taVNS therapy, with no known adverse side effects.  Bioelectronic medicine uses sophisticated technology to modulate the electrical activity of the body’s nervous system and has the potential to supplement or even replace drugs or other interventions.  Evren’s technology is based on stimulating the vagus nerve, the main nerve of the parasympathetic (“calming or safety”) branch of the autonomic nervous system. For further information about the Phoenix CR or Evren Technologies, please visit evrenvns.com. 

CONTACT:

Josh Kelly, Director of Operations

Evren Technologies, Inc.

904.517.2432

Josh.kelly@evrenvns.com